1. Next-generation Alzheimer’s Therapeutics: Leveraging Deep Biology

   • Frank M. Longo
   • Stephen M. Massa

   Editorial Open access 13 May 2020 Pages: 138 - 139

2. A Is for Amyloid

   • D. J. Selkoe

   Editorial 28 April 2020 Pages: 140 - 141

3. An Industry Perspective: Future of Anti-Amyloid Trials

   • Lynn D. Kramer

   Editorial 28 April 2020 Pages: 142 - 143

4. Screening for Mild Cognitive Impairment: There is the Will but Is There a Way?

   • James E. Galvin

   Editorial Open access 06 April 2020 Pages: 144 - 145

5. The Future of Anti-Amyloid Trials

   • P. S. Aisen
   • J. Cummings
   • EU/US CTAD 2019 Task Force

   CTAD Task Force Paper Open access 17 April 2020 Pages: 146 - 151

6. Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report

   • Serge Gauthier
   • P. S. Aisen
   • EU/US CTAD Task Force

   CTAD Task Force Paper Open access 06 April 2020 Pages: 152 - 157

7. Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) supported by Emerging Digital Technologies

   • Marwan N. Sabbagh
   • M. Boada
   • H. Hampel

   Reviews Open access 06 March 2020 Pages: 158 - 164

8. Early Detection of Mild Cognitive Impairment (MCI) in Primary Care

   • Marwan N. Sabbagh
   • M. Boada
   • H. Hampel

   Reviews Open access 06 April 2020 Pages: 165 - 170

9. Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting

   • Marwan N. Sabbagh
   • M. Boada
   • H. Hampel

   Reviews Open access 06 April 2020 Pages: 171 - 178

   

10. Development of an UPSA Short Form for Use in Longitudinal Studies in the Early Alzheimer’s Disease Spectrum

    • T. E. Goldberg
    • P. D. Harvey
    • Jesus J. Gomar

    Original Research 09 January 2020 Pages: 179 - 183

    

11. Targeting Lifestyle Behavior to Improve Brain Health: User-Experiences of an Online Program for Individuals with Subjective Cognitive Decline

    • Linda M. P. Wesselman
    • A. K. Schild
    • S. A. M. Sikkes

    Original Research Open access 02 March 2020 Pages: 184 - 194

    

12. Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business

    • P. S. Aisen
    • R. Raman

    Viewpoint 06 March 2020 Pages: 195 - 196

13. Impact of the Covid-19 Outbreak on the Clinical and Research Activities of Memory Clinics: An Alzheimer’s Disease Center Facing the Covid-19 Crisis

    • Pierre Jean Ousset
    • B. Vellas

    Viewpoint 06 April 2020 Pages: 197 - 198

    

14. The EU/US Task Force’s Future for Anti-Amyloid Trials: Faites Vos Jeux

    • Lon S. Schneider

    Commentary 13 May 2020 Pages: 199 - 200